129 related articles for article (PubMed ID: 38160961)
1. Response to letter to the editor regarding, "Depletion of macrophages deteriorates bisphosphonate-related osteonecrosis of the jaw-like lesions in mice".
Kozutsumi R; Kuroshima S; Al-Omari FA; Hayano H; Nakajima K; Kakehashi H; Sawase T
Bone; 2024 Apr; 181():117010. PubMed ID: 38160961
[No Abstract] [Full Text] [Related]
2. Depletion of macrophages deteriorates BrONJ-like lesions in mice. Bone. 2023 Dec;177:116899.
Pazianas M
Bone; 2024 Apr; 181():116988. PubMed ID: 38070719
[No Abstract] [Full Text] [Related]
3.
Wu S; Li F; Tan J; Ye X; Le Y; Liu N; Everts V; Wan Q
Front Cell Infect Microbiol; 2022; 12():886411. PubMed ID: 35811676
[TBL] [Abstract][Full Text] [Related]
4. Teriparatide and the treatment of bisphosphonate-related osteonecrosis of the jaw: a rat model.
Ersan N; van Ruijven LJ; Bronckers AL; Olgaç V; Ilgüy D; Everts V
Dentomaxillofac Radiol; 2014; 43(1):20130144. PubMed ID: 24170800
[TBL] [Abstract][Full Text] [Related]
5. IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws.
Zhang Q; Atsuta I; Liu S; Chen C; Shi S; Shi S; Le AD
Clin Cancer Res; 2013 Jun; 19(12):3176-88. PubMed ID: 23616636
[TBL] [Abstract][Full Text] [Related]
6. Distinct immunopathology in the early stages between different antiresorptives-related osteonecrosis of the jaw-like lesions in mice.
Hayano H; Kuroshima S; Sasaki M; Tamaki S; Inoue M; Ishisaki A; Sawase T
Bone; 2020 Jun; 135():115308. PubMed ID: 32142911
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of bisphosphonate-related osteonecrosis of the jaw (BRONJ) revealed by targeted removal of legacy bisphosphonate from jawbone using competing inert hydroxymethylene diphosphonate.
Okawa H; Kondo T; Hokugo A; Cherian P; Campagna JJ; Lentini NA; Sung EC; Chiang S; Lin YL; Ebetino FH; John V; Sun S; McKenna CE; Nishimura I
Elife; 2022 Aug; 11():. PubMed ID: 36017995
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin reduces zoledronic acid-induced osteonecrosis of the jaws of rats.
Pazianas M
Bone; 2022 Dec; 165():116561. PubMed ID: 36150658
[No Abstract] [Full Text] [Related]
9. Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function.
Elsayed R; Abraham P; Awad ME; Kurago Z; Baladhandayutham B; Whitford GM; Pashley DH; McKenna CE; Elsalanty ME
Bone; 2018 May; 110():141-149. PubMed ID: 29408511
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate-related osteonecrosis of the jaw.
Robichaux C; Ong M; Veillon D; Patel S; Cotelingam J
J La State Med Soc; 2014; 166(5):200-2. PubMed ID: 25369221
[TBL] [Abstract][Full Text] [Related]
11. Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis.
Aguirre JI; Akhter MP; Kimmel DB; Pingel JE; Williams A; Jorgensen M; Kesavalu L; Wronski TJ
J Bone Miner Res; 2012 Oct; 27(10):2130-43. PubMed ID: 22623376
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.
de Molon RS; Cheong S; Bezouglaia O; Dry SM; Pirih F; Cirelli JA; Aghaloo TL; Tetradis S
Bone; 2014 Nov; 68():11-9. PubMed ID: 25093262
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate exposure and osteonecrosis of the jaw.
Borromeo GL; Brand C; Clement JG; McCullough M; Crighton L; Hepworth G; Wark JD
J Bone Miner Res; 2015 Apr; 30(4):749-50. PubMed ID: 25808734
[No Abstract] [Full Text] [Related]
14. Bisphosphonate exposure and osteonecrosis of the jaw.
Hatton RC; Patel P; Liu W
J Bone Miner Res; 2015 Apr; 30(4):748. PubMed ID: 25808733
[No Abstract] [Full Text] [Related]
15. Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid.
Mozzati M; Martinasso G; Maggiora M; Scoletta M; Zambelli M; Carossa S; Oraldi M; Muzio G; Canuto RA
Clin Oral Investig; 2013 May; 17(4):1259-66. PubMed ID: 22864527
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapeutic and antiresorptive combination therapy suppressed lymphangiogenesis and induced osteonecrosis of the jaw-like lesions in mice.
Kuroshima S; Yamashita J
Bone; 2013 Sep; 56(1):101-9. PubMed ID: 23727433
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid hormone may be a promising therapy for bisphosphonate-related osteonecrosis of jaw bones.
Li YF; Hu J
Int J Oral Maxillofac Surg; 2013 Jan; 42(1):149-50. PubMed ID: 22763138
[No Abstract] [Full Text] [Related]
18. Osteonecrosis of the jaw as a serious adverse effect of bisphosphonate therapy and its indistinct etiopathogenesis.
Gavrić M; Antić S; Jelovac DB; Zarev AI; Petrović MB; Golubović M; Antunović M
Vojnosanit Pregl; 2014 Aug; 71(8):772-6. PubMed ID: 25181838
[No Abstract] [Full Text] [Related]
19. Osteonecrosis of the Jaw Developed in Mice: DISEASE VARIANTS REGULATED BY γδ T CELLS IN ORAL MUCOSAL BARRIER IMMUNITY.
Park S; Kanayama K; Kaur K; Tseng HC; Banankhah S; Quje DT; Sayre JW; Jewett A; Nishimura I
J Biol Chem; 2015 Jul; 290(28):17349-66. PubMed ID: 26013832
[TBL] [Abstract][Full Text] [Related]
20. Medication-related osteonecrosis of the jaw. Introduction of a new modified experimental model.
Curra C; Cardoso CL; Ferreira O; Curi MM; Matsumoto MA; Cavenago BC; Santos PL; Santiago JF
Acta Cir Bras; 2016 May; 31(5):308-13. PubMed ID: 27275851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
